These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8005205)

  • 1. The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research.
    Neumann F
    Exp Clin Endocrinol; 1994; 102(1):1-32. PubMed ID: 8005205
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cyproterone acetate: cardiovascular tolerance].
    Hermabessière J
    Prog Urol; 1992 Apr; 2(2):226-33. PubMed ID: 1302058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cyproterone acetate (Androcur-depo) in the treatment of inoperable prostatic cancer].
    Stepanov VN; Goriunov VG; Chechenin MG; Sivkov AV; Gubdurakhmanov II
    Urol Nefrol (Mosk); 1995; (6):33-6. PubMed ID: 8686122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of cyproterone acetate in animal and clinical trials.
    Neumann F
    Gynecol Invest; 1971; 2(1):150-79. PubMed ID: 4949823
    [No Abstract]   [Full Text] [Related]  

  • 5. Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer.
    Habenicht UF; Schröder H; el Etreby MF; Neumann F
    Prog Clin Biol Res; 1988; 260():63-75. PubMed ID: 2966407
    [No Abstract]   [Full Text] [Related]  

  • 6. [Drug treatment of prostatic carcinoma].
    Kool JC
    Ned Tijdschr Geneeskd; 1997 Nov; 141(45):2202-3. PubMed ID: 9550808
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyproterone acetate in the treatment of sexual disorders: pharmacological base and clinical experience.
    Neumann F; Kalmus J
    Exp Clin Endocrinol; 1991; 98(2):71-80. PubMed ID: 1838080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyproterone acetate--mechanism of action and clinical effectiveness in prostate cancer treatment.
    Schröder FH
    Cancer; 1993 Dec; 72(12 Suppl):3810-5. PubMed ID: 8252496
    [No Abstract]   [Full Text] [Related]  

  • 9. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
    Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
    [No Abstract]   [Full Text] [Related]  

  • 10. Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women: the effect of cyproterone acetate-ethinyl estradiol treatment.
    Luboshitzky R; Herer P; Shen-Orr Z
    Exp Clin Endocrinol Diabetes; 2004 Feb; 112(2):102-7. PubMed ID: 15031776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
    Sugiono M; Winkler MH; Okeke AA; Benney M; Gillatt DA
    Prostate Cancer Prostatic Dis; 2005; 8(1):91-4. PubMed ID: 15711607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of female hyperandrogenism: estroprogestinic therapy at low dose in an inversal sequential scheme.
    Ragonesi FP; Lo Mastro F; Arena V; Ermini M
    Acta Eur Fertil; 1995; 26(4):141-3. PubMed ID: 9098476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology and potential use of cyproterone acetate.
    Neumann F
    Horm Metab Res; 1977 Jan; 9(1):1-13. PubMed ID: 66176
    [No Abstract]   [Full Text] [Related]  

  • 14. [Therapy of virginal prostatic cancer with cyproterone acetate].
    Maier U
    Z Urol Nephrol; 1985 Apr; 78(4):181-7. PubMed ID: 3160180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiandrogens.
    Neri RO
    Adv Sex Horm Res; 1976; 2():233-62. PubMed ID: 65117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cyproterone acetate and cancer of the prostate. Experience in 46 cases].
    Tauveron I; Hermabessière J
    Therapie; 1988 May; 43(3):175-7. PubMed ID: 2971277
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of cyproterone acetate in prostate cancer.
    Goldenberg SL; Bruchovsky N
    Urol Clin North Am; 1991 Feb; 18(1):111-22. PubMed ID: 1825143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyproterone acetate in the management of prostatic cancer.
    Tunn UW
    Prog Clin Biol Res; 1989; 303():105-10. PubMed ID: 2528734
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmacological agents for treatment of paraphilias and hypersexual disorders].
    Hebebrand K; Hebebrand J; Remschmidt H
    Fortschr Neurol Psychiatr; 2002 Sep; 70(9):462-75. PubMed ID: 12215919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Indications, contraindications and legal problems in antiandrogen treatment].
    Vietze G
    Psychiatr Neurol Med Psychol (Leipz); 1976 Nov; 28(11):684-9. PubMed ID: 1035425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.